|
|
|
| Analysis on the Efficacy and Safety of Bevacizumab Combined with Chemotherapy in treatment of Platinum Sensitive Recurrent Ovarian Cancer |
| JIANG Fan, GAO Yang, REN Xiaochen, et al |
| Liaoning Health Industry Group Fushun General Mining Hospita, Liaoning Fushun 113006, China |
|
|
|
|
Abstract Objective: To investigate the clinical efficacy and safety of Bevacizumab combined with chemotherapy in treatment of platinum sensitive recurrent ovarian cancer, and provide a certain reference for clinical treatment. Methods: 80 patients with platinum sensitive recurrent ovarian cancer selected from February 2015 to February 2018, and they were divided into control group and experimental group, which were treated with conventional therapy and bevacizumab combined treatment. After a period of treatment, the clinical efficacy, KPS score and adverse reaction of the two groups were observed. Results: There was no significant difference in cancer control rate between the experimental group and the control group, but the difference of the cancer remission rate was statistically significant (P<0.05). The rate of cancer remission in the experimental group was higher than that of the control group. And there was no significant difference in the adverse reaction of the two groups. The KPS score of the experimental group was higher than that of the control group. The difference was statistically significant (P<0.05). Conclusion: Bevacizumab combined with chemotherapy has certain clinical curative effect in treating platinum sensitive recurrent ovarian cancer, and the patient is well tolerated, so it has certain clinical reference value.
|
|
|
|
|
|
[1] Zhang Q, Madden N E, Wong A S T, et al. The role of endocrine G protein-coupled receptors in ovarian cancer progression [J]. Front Endocrinol,2017, 8(4):66~74.
[2] Jung K W, Won Y J, Kong H J, et al. Cancer statistics in korea: incidence, mortality, survival and prevalence in 2010[J]. Cancer Research & Treatment Official Journal of Korean Cancer Association, 2016, 48(2):436~450.
[3] Aras M, Erdil T Y, Dane F, et al. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors [J]. Nuclear Medicine Communications, 2016, 37(1): 9~15.
[4] 罗永梅,商妮娅.贝伐珠单抗联合吉西他滨治疗晚期铂类耐药复发性卵巢癌效果研究[J].中国处方药,2018,16(1):60~61.
[5] Webb P M, Jordan S J. Epidemiology of epithelial ovarian cancer[J]. Best Practice & Research Clinical Obstetrics & Gynaecology, 2017, 41(5):3~14.
[6] 马丽芳,周琦,李蓉.贝伐单抗联合化疗对铂敏感型复发性卵巢癌的近期疗效及安全性研究[J].重庆医学,2017,46(11):1532~1535.
[7] 任莉,王焱.贝伐单抗联合化疗治疗复发性卵巢癌的临床研究[J].国际医药卫生导报,2017,23(9):1298~1300. |
|
|
|
2019, Vol. 25 
